GlassScriptPhysician profile
Robert E Gumbita
NPI 1922593177
$63,079.19
in general payments reported to CMS, 2019-2025
38 companies · $10K in 2025
The $10K reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $38.54 · 2021: $585 · 2022: $10K · 2023: $22K · 2024: $20K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $38K · Grant: $7,650 · Food and Beverage: $6,669 · Education: $66.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,565.00 |
| Grant | $7,650.00 |
| Food and Beverage | $6,668.88 |
| Education | $66.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Plasma INC. | $37,565.00 | 2023-2025 | |
| Abbott Laboratories | $10,839.76 | 2022-2025 | Tacticath, Xience Skypoint, Cardiomems |
| Csl Behring | $6,215.00 | 2022 | |
| Boston Scientific Corporation | $1,539.02 | 2021-2025 | Watchman Access System, Avvigo Guidance System, Stingray |
| Shockwave Medical, INC | $690.41 | 2022-2025 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave E8 Peripher, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $684.33 | 2021-2025 | Brilinta, Farxiga, Andexxa |
| Janssen Pharmaceuticals, INC | $592.29 | 2020-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $500.62 | 2022-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $500.27 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $499.56 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $441.83 | 2022-2025 | |
| Medtronic, INC. | $435.15 | 2021-2025 | Micra, Corevalve Evolut R, Linq II |
| Actelion Pharmaceuticals US, INC. | $427.91 | 2023-2025 | Opsumit, Uptravi |
| Philips North America LLC | $288.82 | 2023-2025 | Coronary Other |
| Penumbra, INC. | $232.97 | 2024 | Indigo System |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gumbita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.